The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …

Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies,
which has made great achievements in the treatment of malignant tumors. Despite …

Background Chimeric antigen receptor T‐cell (CAR‐T) therapy for acute myeloid leukaemia
(AML) has thus far been elusive, in part due to target restriction and phenotypic …

Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable
therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic …

Simple Summary Chronic myeloid leukemia stem cells (CML LSCs) are a rare and
quiescent population that are resistant to tyrosine kinase inhibitors. CML LSCs have many …

Simple Summary Cell surface proteases (so-called ectoproteases) are associated with
cancer, and their targeting may confer valuable options for the improvement of cancer …

Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is
already widely adopted in clinical practice. On the other hand, the development of CAR-T …

Mutations that occur in RNA-splicing machinery may contribute to hematopoiesis-related
diseases. How splicing factor mutations perturb hematopoiesis, especially in the …

Chimeric antigen receptor T (CAR-T) cell therapy targeting T cell tumors still faces many
challenges, one of which is its fratricide due to the target gene expressed on CAR-T cells …